Enlarge/ Pedestrians walk past Biogen Inc. headquarters in Cambridge, Massachusetts, on Monday, June 7, 2021. Biogen Inc. shares soared after its controversial Alzheimer’s disease therapy was approved by US regulators.
56 with 44 posters participating
Concern…
Controversial Alzheimer’s drug could cost US $334B—nearly half of DoD budget – Ars Technica
Share this article
More News

Crypto Selloff Forces Investors Out
November 21, 2026

(PAYS) Investment Strategy and Analysis
November 21, 2026

Bitcoin falls to two-year low as AI valuation fears spill into crypto
November 21, 2026

(PPLN) Stock Market Analysis
November 21, 2026


(PMIF) Investment Strategy and Analysis
November 21, 2026

$227M in crypto shorts liquidated in four hours as bears get squeezed
November 21, 2026